|
|
| ¤ÙèÁ×Í¢éÒÃÒª¡ÒÃãËÁè | 5 |  | 2.23 |
| advances in pharmacotherapeutics and pharmacy practice 2007 | 4 | | 1.79 |
| ÂÒ | 4 | | 1.79 |
| ¾.Ã.º.ÂÒ ¾.È.2510 | 4 | | 1.79 |
| Êӹѡ§Ò¹¤³Ð¡ÃÃÁ¡ÒÃÍÒËÒÃáÅÐÂÒ | 4 | | 1.79 |
| ÃÒª×èÍà¤Ã×èͧÊÓÍÒ§·Õè Í.Â. »ÃСÒÈËéÒÁãªé | 3 | | 1.34 |
| ¾.Ã.º.ÇèÒ´éÇ¢éÍÊÑÒ·ÕèäÁèà»ç¹¸ÃÃÁ | 3 | | 1.34 |
| ¤ÙèÁ×Í¡ÒÃãªéÂÒÊÒÁÑ»ÃШӺéҹἹ»Ñ¨¨ØºÑ¹ | 3 | | 1.34 |
| »ÃÐÁÇÅ¡®ËÁÒÂáÅÐÃÐàºÕº¡ÒäÅѧ | 3 | | 1.34 |
| ÂÒÊÒÁÑ»ÃШӺéÒ¹ ¢Í͹ØÒµ | 3 | | 1.34 |
| online scanner bitdefender | 3 | | 1.34 |
| ¡ÒÃÍÍ¡Ä·¸Ôì¢Í§ÂÒ | 3 | | 1.34 |
| ÇÔ·ÂÒ¡ÃÊ͹àÃ×èͧà¤ÃÕ´ | 3 | | 1.34 |
| epi info version 6 | 3 | | 1.34 |
| ÍÂ | 3 | | 1.34 |
| à¾Å§ÎÔµ | 3 | | 1.34 |
| à¤Ã×èͧ´×èÁ·ÕèÁÕÊèǹ¼ÊÁ¢Í§¡Òà¿ÍÕ¹ | 3 | | 1.34 |
| ÁÍ¡.255-2521 | 3 | | 1.34 |
| cosmaprof co. ltd. | 3 | | 1.34 |
| ªÓ¹Ò ÀÙèàÍÕèÂÁ 2537 | 2 | | 0.89 |
| ÁÍ¡. 57-2530 | 2 | | 0.89 |
| ÍѹµÃÒ¨ҡàª×éͨØÅÔ¹·ÃÕÂì¡èÍâÃã¹ÍÒËÒà | 2 | | 0.89 |
| Ẻ˹ѧÊ×ÍÅÒÍÍ¡¨Ò¡ÃÒª¡ÒõÒÁÁҵáÒûÃѺ»ÃاÍѵÃÒ¡ÓÅѧ¢Í§ÊèǹÃÒª¡ÒÃ(â¤Ã§¡ÒÃà¡ÉÕ³ÍÒÂØ¡è͹¡Ó˹´)»Õ§º»ÃÐÁÒ³ ¾.È.2553 | 2 | | 0.89 |
| ¿ÍÃìÁ˹ѧÊ×ÍÃѺÃͧ¹Óà¢éÒà¤Ã×èͧÁ×Íá¾·Âì | 2 | | 0.89 |
| ¤ÙèÁ×Í¢éÒÃÒª¡ÒúÃèØãËÁè | 2 | | 0.89 |
| હ¡ÒÃì´ ÃÒ¤Ò áªÁ¾Ù | 2 | | 0.89 |
| á¼¹¡ÒûÃЪØÁÊÑÁÁ¹Ò | 2 | | 0.89 |
| ˹ѧÊ×ͤÇÒÁÅѺ¢Í§âÊÁ | 2 | | 0.89 |
| ÃÇÁà¾Å§ | 2 | | 0.89 |
| ¤ÙèÁ×Ígmp¼ÅÔµÀѳ±ì¹Á¾ÃéÍÁºÃÔâÀ¤ª¹Ô´àËÅÇ | 2 | | 0.89 |
| »ÃÐ⪹ì¢Í§ªÒ´Í¡¤Ó½Í | 2 | | 0.89 |
| »ÃÔÁÒ³ÊÒÃÍÒËÒÃÍéÒ§ÍÔ§·Õè¤ÇÃä´éÃѺ»ÃШÓÇѹ ÊÓËÃѺä·Â ¾.È. 2546 | 2 | | 0.89 |
| »ÃСÒÈ¡ÃзÃǧÊÒ¸ÒóÊØ¢ 2548 ©ºÑº·Õè 16 | 2 | | 0.89 |
| ºÑµÃ»ÃШӵÑǾ¹Ñ¡§Ò¹à¨éÒ˹éÒ·Õè ¾.È.2551 | 2 | | 0.89 |
| ÃÇÁà¾Å§ÎÔµ | 2 | | 0.89 |
| ÍÒËÒÃáÅÐÂÒ | 2 | | 0.89 |
| ÊӹѡÊǹâÁ¡¢¾ÅÒÃÒÁ | 2 | | 0.89 |
| ʺÙèÅéÒ§¤ÇÒÁ·Ø¡¢ì | 2 | | 0.89 |
| ¤ÇÒÁ¤§µÑÇ ÂÒ¹éÓ | 2 | | 0.89 |
| ¹éÓá¢ç§¾Ã»ÃÐä¾ ¹éÓá¢ç§ËÅÍ´µÃÒÅÙ¡âÅ¡ ¹éÓá¢ç§ËÅÍ´µÃÒ¡ÃеèÒ áÅйéÓá¢ç§ËÅÍ´µÃÒ«Ùà»ÍÃìäÍ«ì | 2 | | 0.89 |
| ÇÔ¸Õ ¡Òà ãªé ËéͧÊÁØ´ | 2 | | 0.89 |
| §Ò¹ºÃÔºÒÅàÀÊѪ¡ÃÃÁ ¼Ùé»èÇÂàºÒËÇÒ¹ | 2 | | 0.89 |
| à¤Ã×èͧÁ×Í % salt content | 1 | | 0.45 |
| ËÅǧ»Ùè¨Ñ¹·ÃÒ ¶ÒÇâà | 1 | | 0.45 |
| »¯ÔºÑµÔ§Ò¹¡èÍÊÃéÒ§ | 1 | | 0.45 |
| ciprofloxacin á¾éÂÒ Ãعáç | 1 | | 0.45 |
| Êèǹ¼ÊÁ¹éÓÂÒÅéÒ§àÅçº | 1 | | 0.45 |
| â«áÅÁ | 1 | | 0.45 |
| »ÃÐà·Èä·ÂàµÃÕÂÁ¤ÇÒÁ¾ÃéÍÁà¡ÕèÂǡѺ¡ÒäéÒàÊÃÕ | 1 | | 0.45 |
| ÇѤ«Õ¹»éͧ¡Ñ¹âää¢éÊÁͧÍÑ¡àʺ ¹¾.·ÇÕ | 1 | | 0.45 |
| ⺷çÍ¡ãµéǧᢹ | 1 | | 0.45 |
| ÍѹµÃÒ¨ҡ¹éÓÊéÁÊÒªٻÅÍÁ | 1 | | 0.45 |
| ¼Å¨Ò¡¡ÒùǴàµÕ§俿éÒ | 1 | | 0.45 |
| â·ÉÊÒáѹàª×éÍÃÒã¹ÍÒËÒà | 1 | | 0.45 |
| ·Óà¢ÕéÂÇ | 1 | | 0.45 |
| ä¢éËÇÑ´ãËè2009 | 1 | | 0.45 |
| ÃÒª×èÍÇѵ¶ØÍÍ¡Ä·¸ÔìµèͨԵáÅлÃÐÊÒ· | 1 | | 0.45 |
| warfarin ¤³Ð¡ÃÃÁ¡Òà orfarin | 1 | | 0.45 |
| º.ਠàÁ´ ÍÔÁ¾ÍÃìµ ¨Ó¡Ñ´ | 1 | | 0.45 |
| ä¢éËÇÑ´ãËè h1n1 fda | 1 | | 0.45 |
,
User's Guide
˹éÒÅçÍ¡ÍÔ¹| ʶԵÔÃÒ»Õ
| ʶԵÔÃÒÂà´×͹
| ʶԵÔÃÒÂÇѹ
| ʶԵÔÃÒªÑèÇâÁ§
| Eng
Pageview 
Unique IPs 
Sessions